Diabetes News

Tag: SGLT2 inhibitors

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

March 19th 2016

These data suggest net protection of SGLT2 inhibitors against cardiovascular outcomes and death (The Lancet Diabetes & Endocrinology)

SGLT2 inhibitors: PRAC makes recommendations to minimise risk of diabetic ketoacidosis

February 12th 2016

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has finalised a review of SGLT2 inhibitors (a class of type 2 diabetes medicines) and has made recommendations to minimise the risk of diabetic ketoacidosis (EMA)

Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to insulin degludec/liraglutide

November 3rd 2015

Although the effects differ with each individual class of therapy, clinical trials have shown that adding a glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor or sodium-glucose co-transporter-2 inhibitor to insulin regimens can offer a significant reduction in HbA1c without substantially increasing hypoglycaemia risk, or weight (Diabetic Medicine)

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

SGLT2 inhibitors: PRAC makes recommendations to minimise risk of diabetic ketoacidosis

Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to insulin degludec/liraglutide

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

Glycosmedia is also available as an App:

Sponsorship and Advertising